Novoviah Pharmaceuticals developed the Novoleukin test platform, a 24-hour whole blood assay measuring gluten-specific T cell reactivity via interleukin-2 release to aid celiac disease diagnosis and monitoring. Demonstrated in collaboration with WEHI and published in Gastroenterology, the platform achieved 90% sensitivity and 95% specificity, even in patients on a gluten-free diet who traditionally evade detection by antibody tests. This approach reduces diagnostic burden by potentially eliminating invasive biopsies and dietary requirements.